Home >> Tag Archives: Ventana Medical Systems—

Tag Archives: Ventana Medical Systems—

Horizon, Ventana sign co-development agreement, 11/16

November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.

Read More »

Horizon, Ventana partner on IHC reference standards

Sept. 14, 2016—Horizon Discovery Group has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche Group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as IHC reference standards in cancer tissue diagnostics to support the development and validation of IHC assays. Ventana provides products used in clinical ...

Read More »

Ventana and Astellas join forces, 6/15

June 2015—Ventana Medical Systems has entered into a master collaboration agreement with Astellas Pharma, a research-and-development–driven pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

Read More »

Ventana gets OK for crizotinib IHC companion Dx

June 15, 2015—Ventana Medical Systems announced the FDA’s approval of the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to help identify patients for crizotinib, marketed as Xalkori by Pfizer. The Ventana ALK Assay was approved as a CE-IVD in Europe in 2012 and was approved by the Chinese Food and Drug Administration in 2013. With this class III ...

Read More »

HER2 companion diagnostic, 2/14

February 2014—Ventana Medical Systems’ HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay is a companion diagnostic for detecting HER2 protein expression in patients who, in countries where the drugs are approved, may be appropriate candidates for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine).

Read More »
X